Page last updated: 2024-08-26

fulvestrant and sirolimus

fulvestrant has been researched along with sirolimus in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (20.00)	29.6817
2010's	13 (65.00)	24.3611
2020's	3 (15.00)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E	1
Czubayko, F; Franke, TF; List, HJ; Martin, MB; Morgan, E; Reiter, R; Stoica, A; Stoica, GE; Wellstein, A	1
Perez, EA; Roy, V	1
Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR	1
Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG	1
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE	1
Mehta, A; Tripathy, D	1
Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J	1
Black, EP; Elledge, R; Kadamyan-Melkumian, V; Massarweh, S; Romond, E; Shelton, B; Stevens, M; Van Meter, E	1
Barrow, D; Dutkowski, CM; Gee, JM; Guichard, SM; Hutcheson, IR; Jordan, NJ; Mottram, HJ; Nicholson, RI	1
Al-Qaisi, A; Awasthi, M; Chen, A; Chen, L; Kadamyan-Melkumyan, V; Massarweh, S; Romond, E	1
Anur, P; Biswal, NC; Contreras, A; Creighton, CJ; Davies, BR; Fu, X; Giuliano, M; Gray, JW; Guichard, SM; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Joshi, A; Karlin, KL; Klinowska, T; Kumar, V; Lee, AV; Mills, GB; Morrison, G; Nanda, S; Nardone, A; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Smith, PD; Spellman, P; Wang, T; Westbrook, TF	1
Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P	1
Anderson, L; Chen, D; Conklin, D; Dering, J; Desai, AJ; Finn, RS; Hurvitz, SA; Kalous, O; Kolarova, T; Linnartz, R; O'Brien, NA; Slamon, DJ	1
Bachelot, T; Bally, O; Heudel, P; Kassem, L; Tredan, O; Vanacker, H	1
O'Leary, KA; Schuler, LA; Shea, MP; Vezina, CM; Wegner, KA	1
Antunes, F; Bincoletto, C; Guarache, GC; Muler, ML; Oliveira, RB; Pereira, GJDS; Smaili, SS; Ureshino, RP	1
Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J	1

Reviews

6 review(s) available for fulvestrant and sirolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
New therapies in the treatment of breast cancer. Seminars in oncology, 2006, Volume: 33, Issue:3 Suppl 9 Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Paclitaxel; Sirolimus; Vinblastine	2006
Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles	2014
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast cancer research and treatment, 2014, Volume: 143, Issue:1 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome	2014
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. Cancer treatment reviews, 2015, Volume: 41, Issue:2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles	2015
[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Suppl 1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Histone Demethylases; Humans; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; TOR Serine-Threonine Kinases	2015

Trials

3 trial(s) available for fulvestrant and sirolimus

Article	Year
Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate	2012
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast cancer research and treatment, 2014, Volume: 143, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure	2014
Everolimus-induced hematologic changes in patients with metastatic breast cancer. Clinical breast cancer, 2015, Volume: 15, Issue:1 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Erythrocyte Count; Erythrocyte Indices; Estradiol; Everolimus; Female; Fulvestrant; Hematologic Diseases; Humans; Leukocyte Count; Leukopenia; Neoplasm Metastasis; Sirolimus; Thrombocytopenia	2015

Other Studies

11 other study(ies) available for fulvestrant and sirolimus

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved? European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2	2021
Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:5 Topics: Androstadienes; Breast Neoplasms; Chromones; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Genistein; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Isoforms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Serine; Signal Transduction; Sirolimus; Tumor Cells, Cultured; Tyrphostins; Wortmannin	2003
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:8 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles	2007
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast cancer research : BCR, 2011, Mar-01, Volume: 13, Issue:2 Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2011
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast cancer research : BCR, 2014, Jan-23, Volume: 16, Issue:1 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases	2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast cancer research : BCR, 2014, Sep-11, Volume: 16, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doxycycline; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2014
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast cancer research and treatment, 2015, Volume: 149, Issue:3 Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays	2015
High collagen density augments mTOR-dependent cancer stem cells in ERα+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer letters, 2018, 10-01, Volume: 433 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Microenvironment	2018
Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells. Einstein (Sao Paulo, Brazil), 2020, Volume: 18 Topics: Analysis of Variance; Autophagy; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Flow Cytometry; Fulvestrant; Humans; MCF-7 Cells; Receptors, G-Protein-Coupled; Reproducibility of Results; Sirolimus; Time Factors; Transfection	2020
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast (Edinburgh, Scotland), 2020, Volume: 52 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; China; Circulating Tumor DNA; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Retrospective Studies; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Toremifene	2020